Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) FCF Margin (2016 - 2025)

Fate Therapeutics (FATE) has disclosed FCF Margin for 14 consecutive years, with 1355.22% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 14601.0% year-over-year to 1355.22%, compared with a TTM value of 1596.21% through Dec 2025, down 69375.0%, and an annual FY2025 reading of 1596.21%, down 69375.0% over the prior year.
  • FCF Margin was 1355.22% for Q4 2025 at Fate Therapeutics, up from 1526.54% in the prior quarter.
  • Across five years, FCF Margin topped out at 54.37% in Q1 2023 and bottomed at 2775.67% in Q2 2023.
  • Average FCF Margin over 5 years is 1038.01%, with a median of 715.98% recorded in 2024.
  • The sharpest move saw FCF Margin crashed -249937bps in 2023, then soared 229680bps in 2024.
  • Year by year, FCF Margin stood at 247.99% in 2021, then surged by 32bps to 167.86% in 2022, then crashed by -1415bps to 2543.08% in 2023, then surged by 41bps to 1501.24% in 2024, then increased by 10bps to 1355.22% in 2025.
  • Business Quant data shows FCF Margin for FATE at 1355.22% in Q4 2025, 1526.54% in Q3 2025, and 1360.72% in Q2 2025.